OptiBiotix Health PLC Agreement with global corporate for SweetBiotix® (5010S)

TIDMOPTI

RNS Number : 5010S

OptiBiotix Health PLC

26 June 2018

26 June 2018

OptiBiotix Health plc

("OptiBiotix" or the Company")

Agreement with global corporate for SweetBiotix(R)

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces that it has entered into an agreement with a global corporate for its SweetBiotix(R) low calorie sweet fibres. The agreement sets out the terms and grants exclusivity, for a period of six months, to negotiate a license agreement for the scale up, manufacture and distribution of its SweetBiotix(R) low calorie sweet fibres. OptiBiotix will receive monthly payments during this exclusivity period amounting to a six figure sum.

OptiBiotix has previously announced (RNS: 27 March 2018) that it has carried out five successful human taste studies on a range of products developed from its SweetBiotix(R) development programmes. This has created interest from a number of corporates with expertise in the manufacture and commercialisation of speciality ingredients and/or consumer products. This agreement reflects the materialisation of interest from one of these companies in scaling up, manufacturing and distributing SweetBiotix(R) from one of its development programmes.

The company is a global supplier of nutritional and agricultural products to companies around the world with an annual turnover exceeding $100bn. The organisation requires its identity and the terms of the agreement to remain confidential and no further details can be disclosed. A further announcement will be made in due course.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the signing of this agreement for SweetBiotix(R) with one of the world's largest suppliers of nutritional and agricultural products. This is the second agreement with global partners for products created from our SweetBiotix(R) development programmes. This is part of a strategy of working with global partners to support scale up, manufacture and commercialisation of a range of SweetBiotix(R) products in well-known consumer brands. With international concerns over the balance of sugars and fibres in consumer diets rising, OptiBiotix's is at the forefront of product development in this area of growing industry and commercial interest."

For further information, please contact:

 
 OptiBiotix Health plc                                               www.optibiotix.com 
 Stephen O'Hara, Chief Executive                                   Contact via Walbrook 
                                                                                  below 
 
 Cairn Financial Advisers LLP (NOMAD)                                Tel: [phone] 
 Liam Murray / Jo Turner 
 
   finnCap (Broker)                                                  Tel: [phone] 
 Adrian Hargrave / Scott Mathieson / Kate Bannatyne 
  (Corporate Finance) 
 Abigail Wayne (Corporate Broking) 
 
 Walbrook PR Ltd                        Tel: [phone] or [e-mail] 
 Anna Dunphy                                                         Mob: [phone] 
 
 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen(R) and OptiBiotic(R) platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

AGRBXGDLBUDBGIU

(END) Dow Jones Newswires

June 26, 2018 02:00 ET (06:00 GMT)